Relyvrio, a new drug to treat ALS, has been approved by the FDA, giving patients a new option that may slow progression of the fatal degenerative disease
Amylyx Pharmaceuticals Inc.
will charge at least $158,000 annually for its newly approved drugThe drug, called Relyvrio, was approved by the Food and Drug Administration late Thursday afterabout whether there was enough evidence to show the drug works. It is the first new treatment in five years for ALS, which is also known as Lou Gehrig’s disease, and promises to slow its progression and extend the lives of patients by several months.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: